The drug is a relatively new synthetic opioid that poses significant risks to community well-being . The regulatory standing remains complex and differs greatly across jurisdictions . Currently , K2 is generally manufactured in clandestine labs located in Asia , although this frequently appears on the copyright in various countries , including the